
Contents

CHAPTER 1

Autologous Serum Eyedrops for Ocular Surface Disorders

GERD GEERLING, DIRK HARTWIG

1.1	Introduction	2
1.1.1	The Rationale for Using Serum in Ocular Surface Disorders	2
1.1.2	Legal Aspects	3
1.2	Production and Application	4
1.2.1	Important Parameters of the Production Process	4
1.2.2	Current Standard Operating Procedures Used at the University of Lübeck	6
1.2.3	Quality Control	8
1.3	Clinical Results	8
1.3.1	Persistent Epithelial Defects	8
1.3.2	Dry Eye	10
1.3.3	Other Indications	13
1.4	Complications	15
1.5	Alternative Blood Products for the Treatment of Ocular Surface Disease	16
1.5.1	Umbilical Chord Serum	16
1.5.2	Albumin	17
1.5.3	Plasma and Platelets	17
	References	18

CHAPTER 2

Controversies and Limitations of Amniotic Membrane in Ophthalmic Surgery

HARMINDER S. DUA, V. SENTHIL MAHARAJAN,
ANDY HOPKINSON

2.1	Introduction	21
2.2	Proposed Mechanisms of Action of the Amniotic Membrane	22
2.2.1	Amnion Structure	22
2.2.2	Amnion Composition	22

2.3	Intra and Inter Donor Variations of the Membrane	24
2.4	Processing and Preservation of the Membrane	25
2.5	Clinical Studies and Outcomes (Definitions of Success and Grading of Disease Severity)	27
2.6	Efficacy of Membrane in Relation to Other Established Techniques and Options	30
	References	31

CHAPTER 3

Transplantation of Limbal Stem Cells

HARMINDER S. DUA

3.1	Introduction	36
3.2	Stem Cells	36
3.2.1	Definition	36
3.2.2	Characteristics of Stem Cells	36
3.2.3	The Stem Cell 'Niche'	37
3.3	Limbal Stem Cells	37
3.3.1	The Clinical Evidence	37
3.3.2	The Scientific Evidence	39
3.4	Limbal Stem Cell Deficiency	41
3.4.1	Causes of Limbal Stem Cell Deficiency	41
3.4.2	Effects of Limbal Stem Cell Deficiency	41
3.4.3	Diagnosis of Stem Cell Deficiency	44
3.5	Limbal Transplant Surgery	45
3.5.1	Principles	45
3.5.2	Preoperative Considerations	45
3.6	Surgical Techniques	46
3.6.1	Sequential Sector Conjunctival Epitheliectomy (SSCE)	46
3.6.2	Auto-limbal Transplantation	48
3.6.3	Allo-limbal Transplantation	49
3.6.4	Adjunctive Surgery	51
3.6.5	Postoperative Treatment	52
	References	53

CHAPTER 4

Limbal Stem Cell Culture

JOSÉ L. GÜELL, MARTA TORRABADELLA,
MARTA CALATAYUD, OSCAR GRIS,
FELICIDAD MANERO, JAVIER GAYTAN

4.1	Introduction	57
4.2	Epithelial Phenotype	58
4.3	Preparation of Human Amniotic Membrane	58
4.4	Culture of Explanted Tissue	59
4.5	Tissue Procurement	59
4.6	Preliminary Clinical Experience ...	60
4.6.1	Principles for Taking the Biopsy ...	60
4.6.2	Advantages of Limbal Stem Cell Culture	61
4.7	Case Report	61
4.8	Future Standard Staging Approach for Ocular Surface Reconstruction .	64
	References	64

CHAPTER 5

Deep Anterior Lamellar Keratoplasty

GERRIT R.J. MELLES

5.1	Introduction	65
5.2	Main Drawbacks of Conventional DALK	65
5.3	Different Concepts	65
5.4	Important Preoperative Considerations	66
5.5	Psychological Preparation of the Patient	67
5.6	Choice of DALK Surgical Technique	67
5.7	Clinical Results	68
	References	70

CHAPTER 6

Corneal Transplant Rejection

T.P.A.M. SLEGGERS, M.K. DALY, D.F.P. LARKIN

6.1	Introduction	73
6.2	Incidence	74
6.3	Factors Predisposing to Corneal Graft Rejection	74
6.4	Clinical Features	75
6.5	Histopathology	75

6.6	Immunopathological Mechanisms	76
6.6.1	Immune Privilege and Its Breakdown	76
6.6.2	Afferent Arm of the Allogeneic Response	76
6.6.3	Efferent Arm of the Allogeneic Response	77
6.7	Treatment of Rejection	77
6.8	Prevention of Rejection	77
6.8.1	Immunosuppression	77
6.8.2	HLA Matching	78
6.9	Future Prospects	78
	References	79

CHAPTER 7

New Aspects of Angiogenesis in the Cornea

CLAUS CURSIEFEN, FRIEDRICH E. KRUSE

7.1	Introduction	83
7.2	“Angiogenic Privilege of the Cornea” or “How Does the Normal Cornea Maintain Its Avascularity?”	84
7.3	Corneal (Hem)angiogenesis	85
7.3.1	General Mechanisms of Corneal (Hem)angiogenesis	85
7.3.2	Common Causes of Corneal (Hem)angiogenesis	86
7.3.3	Clinical Consequences of Corneal Hemangiogenesis	86
7.3.4	Corneal Hemangiogenesis After Keratoplasty	87
7.3.5	Corneal Angiogenesis Due to Contact Lens Wear	90
7.3.6	Angiogenesis as a Cause of Disease Progression, not a Sequel (Herpetic Keratitis) ..	91
7.3.7	Surgery in Vascularized Corneas ..	91
7.4	Corneal Lymphangiogenesis	91
7.4.1	Mechanisms of Corneal Lymphangiogenesis	91
7.4.2	Importance of Lymphangiogenesis for Induction of Alloimmunity After Keratoplasty	94
7.4.3	Non-immunological Effects of Corneal Lymphangiogenesis ...	94
7.5	Antiangiogenic Therapy at the Cornea	95
7.5.1	Established and Novel Antiangiogenic Therapies	95

7.5.2 Novel Antihemangiogenic and Antilymphangiogenic Therapies to Improve Graft Survival After Keratoplasty 98
 References 98

**CHAPTER 8
 Histocompatibility Matching in Penetrating Keratoplasty**

DANIEL BÖHRINGER, RAINER SUNDMACHER, THOMAS REINHARD

8.1 Introduction 101
 8.1.1 Immune Reactions Constantly Threaten Graft Survival 101
 8.1.2 Major Transplantation Antigens (HLA) 102
 8.1.3 Minor Transplantation Antigens .. 105
 8.2 Time on the Waiting List Associated with Histocompatibility Matching . 106
 8.2.1 Waiting Time Variance Has Been a Barrier to Histocompatibility Matching 106
 8.2.2 Algorithm for Predicting the Time on the Waiting List 106
 8.3 Recommended Clinical Practice ... 107
 References 108

**CHAPTER 9
 Current Systemic Immunosuppressive Strategies in Penetrating Keratoplasty**

ALEXANDER REIS, THOMAS REINHARD

9.1 Introduction 109
 9.2 Immunology 109
 9.2.1 Acute Rejection 110
 9.2.2 Major Histocompatibility Complex 110
 9.2.3 Chronic Rejection 110
 9.3 Normal-Risk Versus High-Risk Transplantation 111
 9.3.1 Normal-Risk Transplantation 111
 9.3.2 High-Risk Transplantation 111
 9.3.3 Rationale for Systemic Immunosuppression 111
 9.3.4 Why Is Immunomodulation with Topical Steroids Not Sufficient To Prevent Immunologic Graft Rejection in High-Risk Patients? .. 111

9.4 Immunosuppressive Agents 112
 9.4.1 History 112
 9.4.2 Corticosteroids 114
 9.4.3 Cyclosporine A (CSA, Sandimmun, Sandimmun Optoral, Sandimmun Neoral) 114
 9.4.4 Tacrolimus (FK506, Prograf) 114
 9.4.5 Mycophenolate Mofetil (MMF, CellCept, Myfortic) 115
 9.4.6 Rapamycin (Sirolimus, Rapamune) 115
 9.4.7 RAD (Everolimus, Certican) 116
 9.4.8 FTY 720 116
 9.4.9 Biologic Agents 117
 9.5 Guidelines for Practitioners 117
 9.5.1 Preoperative Evaluation 117
 9.5.2 How To Use Cyclosporine in High-Risk Corneal Transplantation 118
 9.5.3 How To Use MMF in High-Risk Corneal Transplantation 118
 9.5.4 How To Use Rapamycin in High-Risk Corneal Transplantation 118
 9.5.5 How To Use Tacrolimus in High-Risk Corneal Transplantation 118
 9.5.6 Combination Therapies 119
 9.6 Conclusion 119
 References 119

**CHAPTER 10
 Trephination in Penetrating Keratoplasty**

BERTHOLD SEITZ, ACHIM LANGENBUCHER, GOTTFRIED O.H. NAUMANN

10.1 Introduction 123
 10.2 Astigmatism and Keratoplasty ... 124
 10.2.1 Definition of Post-keratoplasty Astigmatism 124
 10.2.2 Reasons for Astigmatism After Keratoplasty 125
 10.2.3 Prevention/Prophylaxis of Astigmatism After Keratoplasty 129
 10.3 Trephination Techniques 130
 10.3.1 Principal Considerations 131
 10.3.2 Conventional Mechanical Trephines 139
 10.3.3 Nonmechanical Laser Trephination 144
 10.4 Concluding Remarks 148
 References 149

CHAPTER 11

Infective Complications Following LASIK

ADAM WATSON, SHERAZ DAYA

11.1 Introduction 153
 11.2 Frequency and Presentation 153
 11.3 Characteristics 154
 11.4 Differential Diagnosis 154
 11.4.1 Diffuse Lamellar Keratitis (DLK, “Sands of the Sahara”) 154
 11.4.2 Steroid-Induced Intraocular Pressure Elevation with Flap Oedema (Pseudo-DLK) . 155
 11.5 Management 155
 11.5.1 Flap Lift 155
 11.5.2 Specimen Taking 155
 11.5.3 Treatment 157
 11.5.4 No Improvement 157
 11.6 Special Considerations 158
 11.6.2 Fungal Keratitis 158
 11.6.3 Viral Keratitis 159
 11.7 Visual Outcome 159
 11.8 Management of Sequelae 159
 11.9 Prevention 160
 References 160

CHAPTER 12

Treatment of Adenoviral Keratoconjunctivitis

JOST HILLENKAMP, RAINER SUNDMACHER, THOMAS REINHARD

12.1 Introduction 163
 12.1.1 Etiology and Clinical Course of Ocular Adenoviral Infection 163
 12.2 Socioeconomic Aspect 166
 12.3 Treatment 166
 12.3.1 Treatment of the Acute Phase 166
 12.3.2 Treatment of the Chronic Phase ... 168
 12.3.3 Prophylaxis 169
 12.4 Conclusion and Outlook 170
 12.5 Current Clinical Practice and Recommendations 170
 References 170

CHAPTER 13

In Vivo Micromorphology of the Cornea: Confocal Microscopy Principles and Clinical Applications

RUDOLF F. GUTHOFF, JOACHIM STAVE

13.1 Introduction 173
 13.2 Principle of In Vivo Confocal Microscopy Based on the Laser-Scanning Technique . 174
 13.2.1 Slit-Scanning Techniques 175
 13.2.2 Laser-Scanning Microscopy and Pachymetry 176
 13.2.3 Fundamentals of Image Formation in In Vivo Confocal Microscopy ... 179
 13.3 General Anatomical Considerations 180
 13.4 In Vivo Confocal Laser-Scanning Microscopy 181
 13.4.1 Confocal Laser-Scanning Imaging of Normal Structures 182
 13.5 Clinical Findings 190
 13.5.1 Dry Eye 190
 13.5.2 Meesmann’s Dystrophy 190
 13.5.3 Epithelium in Contact Lens Wearers 192
 13.5.4 Epidemic Keratoconjunctivitis ... 195
 13.5.5 Acanthamoeba Keratitis 196
 13.5.6 Corneal Ulcer 199
 13.5.7 Refractive Corneal Surgery 200
 13.6 Future Developments 201
 13.6.1 Three-Dimensional Confocal Laser-Scanning Microscopy 201
 13.6.2 Functional Imaging 203
 References 206

CHAPTER 14
Allergic Eye Disease: Pathophysiology,
Clinical Manifestations and Treatment
 BITA MANZOURI, THOMAS FLYNN,
 SANTA JEREMY ONO

14.1 Introduction 209
 14.2 Pathophysiology 210
 14.2.1 Type I Hypersensitivity 210
 14.2.2 Ocular Inflammatory Reaction:
 Late Phase 211
 14.2.3 Non-specific Conjunctival
 Hyperreactivity 211
 14.2.4 T-Cell-Mediated Hypersensitivity
 in Allergic Eye Disease 212
 14.3 Clinical Syndromes
 of Allergic Eye Disease 212
 14.3.1 Seasonal Allergic Conjunctivitis ... 214

14.3.2 Perennial Allergic Conjunctivitis .. 214
 14.3.3 Vernal Keratoconjunctivitis 214
 14.3.4 Atopic Keratoconjunctivitis 215
 14.3.5 Giant Papillary Conjunctivitis 217
 14.4 Treatment of Allergic Eye Disease . 217
 14.4.1 Antihistamines 218
 14.4.2 Mast Cell Stabilizing Agents 218
 14.4.3 Dual-Acting Agents 219
 14.4.4 Non-steroidal Anti-inflammatory
 Drugs (NSAIDs) 219
 14.4.5 Topical Corticosteroids 219
 14.4.6 Calcineurin Inhibitors 220
 14.4.7 Future Drug Developments 220
 14.5 Conclusion 221
 References 222

Subject Index 225